Edition:
United States

Aeglea Bio Therapeutics Inc (AGLE.OQ)

AGLE.OQ on NASDAQ Stock Exchange Global Market

9.42USD
19 Jul 2018
Change (% chg)

$0.06 (+0.64%)
Prev Close
$9.36
Open
$9.32
Day's High
$9.43
Day's Low
$9.32
Volume
3,369
Avg. Vol
75,201
52-wk High
$12.00
52-wk Low
$2.81

Latest Key Developments (Source: Significant Developments)

Aeglea Biotherapeutics Prices Public Offering Of Common Stock
Wednesday, 18 Apr 2018 10:49pm EDT 

April 18 (Reuters) - Aeglea Bio Therapeutics Inc ::AEGLEA BIOTHERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 4.50 MILLION COMMON SHARES PRICED AT $8.00PER SHARE.  Full Article

Aeglea Biotherapeutics Q4 Revenue $1.5 Mln Vs $1.2 Mln
Tuesday, 13 Mar 2018 07:00am EDT 

March 13 (Reuters) - Aeglea Bio Therapeutics Inc ::AEGLEA BIOTHERAPEUTICS PROVIDES KEY CLINICAL DATA UPDATE FROM PHASE 1/2 TRIAL IN ARGINASE 1 DEFICIENCY AND REPORTS Q4 AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 REVENUE $1.5 MILLION VERSUS $1.2 MILLION.Q4 REVENUE VIEW $1.2 MILLION -- THOMSON REUTERS I/B/E/S.‍REPEAT DOSES OF COMPANY'S PEGZILARGINASE PRODUCES MARKED AND SUSTAINED REDUCTIONS IN PLASMA ARGININE LEVELS​.‍ACCOMPANYING REDUCTIONS IN OTHER RELATED GUANIDINO COMPOUNDS ALSO SEEN IN STUDY​.‍EXPECTS TO REPORT PEDIATRIC AND ADULT REPEAT DOSE DATA IN PATIENTS WITH ARGINASE 1 DEFICIENCY IN Q3 2018​.AEGLEA BIO - ‍AS OF DEC 31, 2017, HAD AVAILABLE CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $50.3 MILLION​.AEGLEA BIO THERAPEUTICS - BASED ON CURRENT OPERATING PLAN, BELIEVES HAS SUFFICIENT CAPITAL RESOURCES TO FUND ANTICIPATED OPERATIONS THROUGH Q3 2019.NET LOSS TOTALED $6.5 MILLION AND $5.5 MILLION FOR Q4 OF 2017 AND 2016, RESPECTIVELY.  Full Article

Aeglea Biotherapeutics announces clinical collaboration with Merck
Monday, 16 Oct 2017 08:00am EDT 

Oct 16 (Reuters) - Aeglea Bio Therapeutics Inc :Aeglea Biotherapeutics announces clinical collaboration with Merck to evaluate the combination of Aeglea’S AEB1102 (pegzilarginase) with Merck's Keytruda® (pembrolizumab) for the treatment of small cell lung cancer.Aeglea Bio Therapeutics Inc - ‍collaboration agreement is between Aeglea Biotherapeutics and Merck, through a subsidiary​.Aeglea Bio Therapeutics Inc - ‍additional details of collaboration were not disclosed​.Aeglea Bio Therapeutics Inc - ‍enrollment to multicenter phase 1/2 study​ is expected to begin in Q1 of 2018.  Full Article

Aeglea Biotherapeutics Qtrly loss per share $0.46
Tuesday, 9 Aug 2016 06:00am EDT 

Aeglea Bio Therapeutics Inc : Aeglea biotherapeutics announces second quarter 2016 financial results . Q2 revenue $1.4 million versus $3.4 million . Qtrly loss per share $0.46 .Management believes that co has sufficient capital resources to fund anticipated operations through q1 of 2018.  Full Article

BRIEF-Aeglea Biotherapeutics Announces Proposed Public Offering

* AEGLEA BIOTHERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK